{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T21:45:10Z","timestamp":1794260710507,"version":"4.9.0"},"reference-count":170,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.annonc.2025.10.1239","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T16:56:24Z","timestamp":1762361784000},"page":"314-328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Intratumoral heterogeneity and immunotherapy resistance: clinical implications"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6075-489X","authenticated-orcid":false,"given":"B.P.","family":"Keenan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2168-8177","authenticated-orcid":false,"given":"M.","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7178-8777","authenticated-orcid":false,"given":"G.","family":"Ansstas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Fabrizio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Murugesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Montesion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Guha Niyogi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6132-7299","authenticated-orcid":false,"given":"I.","family":"Mellman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Melero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.annonc.2025.10.1239_bib1","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"issue":"22","key":"10.1016\/j.annonc.2025.10.1239_bib2","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1158\/1078-0432.CCR-11-1595","article-title":"Ipilimumab: an anti-CTLA-4 antibody for metastatic melanoma","volume":"17","author":"Lipson","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"7378","key":"10.1016\/j.annonc.2025.10.1239_bib3","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"issue":"26","key":"10.1016\/j.annonc.2025.10.1239_bib4","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.annonc.2025.10.1239_bib5","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"10183","key":"10.1016\/j.annonc.2025.10.1239_bib6","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.annonc.2025.10.1239_bib7","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.1200\/JCO.20.03555","article-title":"Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I\/II study","volume":"39","author":"Kelley","year":"2021","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.annonc.2025.10.1239_bib8","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.annonc.2025.10.1239_bib9","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/S1470-2045(19)30413-9","article-title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial","volume":"20","author":"Motzer","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2025.10.1239_bib10","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/S1470-2045(19)30407-3","article-title":"Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis","volume":"20","author":"Antonia","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1239_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce","volume":"8","author":"Kluger","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.annonc.2025.10.1239_bib12","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.annonc.2025.10.1239_bib13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"issue":"7681","key":"10.1016\/j.annonc.2025.10.1239_bib14","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/nature24462","article-title":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer","volume":"551","author":"Balachandran","year":"2017","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.annonc.2025.10.1239_bib15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ccell.2020.03.017","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"Schoenfeld","year":"2020","journal-title":"Cancer Cell"},{"issue":"4","key":"10.1016\/j.annonc.2025.10.1239_bib16","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2020.03.007","article-title":"Intratumor heterogeneity: the Rosetta stone of therapy resistance","volume":"37","author":"Marusyk","year":"2020","journal-title":"Cancer Cell"},{"issue":"18","key":"10.1016\/j.annonc.2025.10.1239_bib17","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2021108389","article-title":"Cancer evolution: Darwin and beyond","volume":"40","author":"Vendramin","year":"2021","journal-title":"EMBO J"},{"issue":"10","key":"10.1016\/j.annonc.2025.10.1239_bib18","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/s41568-024-00734-2","article-title":"The evolutionary theory of cancer: challenges and potential solutions","volume":"24","author":"Laplane","year":"2024","journal-title":"Nat Rev Cancer"},{"issue":"10","key":"10.1016\/j.annonc.2025.10.1239_bib19","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1158\/2159-8290.CD-19-1366","article-title":"Immune surveillance in clinical regression of preinvasive squamous cell lung cancer","volume":"10","author":"Pennycuick","year":"2020","journal-title":"Cancer Discov"},{"issue":"12","key":"10.1016\/j.annonc.2025.10.1239_bib20","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1038\/nrc2013","article-title":"Cancer as an evolutionary and ecological process","volume":"6","author":"Merlo","year":"2006","journal-title":"Nat Rev Cancer"},{"issue":"4260","key":"10.1016\/j.annonc.2025.10.1239_bib21","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1126\/science.959840","article-title":"The clonal evolution of tumor cell populations","volume":"194","author":"Nowell","year":"1976","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.annonc.2025.10.1239_bib22","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1016\/j.immuni.2023.09.004","article-title":"Cancer cell-intrinsic mechanisms driving acquired immune tolerance","volume":"56","author":"Ghorani","year":"2023","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.annonc.2025.10.1239_bib23","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.annonc.2025.10.1239_bib24","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-immunol-041015-055318","article-title":"CD8 T cell exhaustion during chronic viral infection and cancer","volume":"37","author":"McLane","year":"2019","journal-title":"Annu Rev Immunol"},{"issue":"2","key":"10.1016\/j.annonc.2025.10.1239_bib25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.immuni.2004.07.017","article-title":"The immunobiology of cancer immunosurveillance and immunoediting","volume":"21","author":"Dunn","year":"2004","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.annonc.2025.10.1239_bib26","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.cell.2017.09.028","article-title":"Tumor and microenvironment evolution during immunotherapy with nivolumab","volume":"171","author":"Riaz","year":"2017","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.annonc.2025.10.1239_bib27","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.annonc.2025.10.1239_bib28","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1158\/2159-8290.CD-23-1380","article-title":"Spatial architecture of myeloid and T cells orchestrates immune evasion and clinical outcome in lung cancer","volume":"14","author":"Enfield","year":"2024","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.annonc.2025.10.1239_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2022.07.766","article-title":"Evaluation of tumor heterogeneity (TH) as a prognostic biomarker in osimertinib treated non-small cell lung cancer patients","volume":"17","author":"Murugesan","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1239_bib30","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ccell.2023.11.010","article-title":"Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinoma","volume":"42","author":"Sun","year":"2024","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.annonc.2025.10.1239_bib31","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1002\/1878-0261.12375","article-title":"Intratumor heterogeneity defines treatment-resistant HER2+ breast tumors","volume":"12","author":"Rye","year":"2018","journal-title":"Mol Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2025.10.1239_bib32","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.cell.2017.08.012","article-title":"Cancer evolution constrained by the immune microenvironment","volume":"170","author":"McGranahan","year":"2017","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.annonc.2025.10.1239_bib33","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1239_bib34","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1038\/s41467-018-06300-3","article-title":"Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA","volume":"9","author":"Paulson","year":"2018","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.annonc.2025.10.1239_bib35","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.annonc.2025.10.1239_bib36","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1038\/s41588-024-01883-8","article-title":"MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution","volume":"56","author":"Puttick","year":"2024","journal-title":"Nat Genet"},{"issue":"2","key":"10.1016\/j.annonc.2025.10.1239_bib37","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1158\/2159-8290.CD-23-1541","article-title":"The evolutionary forest of pancreatic cancer","volume":"15","author":"Mullen","year":"2025","journal-title":"Cancer Discov"},{"issue":"7934","key":"10.1016\/j.annonc.2025.10.1239_bib38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","article-title":"Neoadjuvant relatlimab and nivolumab in resectable melanoma","volume":"611","author":"Amaria","year":"2022","journal-title":"Nature"},{"issue":"21","key":"10.1016\/j.annonc.2025.10.1239_bib39","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.annonc.2025.10.1239_bib40","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2211437","article-title":"Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma","volume":"388","author":"Patel","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.annonc.2025.10.1239_bib41","doi-asserted-by":"crossref","first-page":"758","DOI":"10.5306\/wjco.v13.i9.758","article-title":"Neoadjuvant immunotherapy in non-small-cell lung cancer: times are changing\u2014and fast","volume":"13","author":"Aguado","year":"2022","journal-title":"World J Clin Oncol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2025.10.1239_bib42","article-title":"Neoadjuvant immunotherapy in hepatocellular carcinoma: a systematic review and meta-analysis","volume":"41","author":"Parekh","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7963","key":"10.1016\/j.annonc.2025.10.1239_bib43","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"issue":"10427","key":"10.1016\/j.annonc.2025.10.1239_bib44","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"issue":"8054","key":"10.1016\/j.annonc.2025.10.1239_bib45","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-024-08507-5","article-title":"A neoantigen vaccine generates antitumour immunity in renal cell carcinoma","volume":"639","author":"Braun","year":"2025","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.annonc.2025.10.1239_bib46","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/1078-0432.CCR-07-1127","article-title":"Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution","volume":"14","author":"Allred","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"8012","key":"10.1016\/j.annonc.2025.10.1239_bib47","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-024-07359-3","article-title":"3D genomic mapping reveals multifocality of human pancreatic precancers","volume":"629","author":"Braxton","year":"2024","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.annonc.2025.10.1239_bib48","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/(SICI)1096-9896(199703)181:3<281::AID-PATH777>3.0.CO;2-M","article-title":"Genetic heterogeneity in sporadic colorectal adenomas","volume":"181","author":"Saraga","year":"1997","journal-title":"J Pathol"},{"issue":"3","key":"10.1016\/j.annonc.2025.10.1239_bib49","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41591-018-0323-0","article-title":"Deciphering the genomic, epigenomic, and transcriptomic landscapes of pre-invasive lung cancer lesions","volume":"25","author":"Teixeira","year":"2019","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.annonc.2025.10.1239_bib50","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1158\/1940-6207.CAPR-22-0469","article-title":"Clonal evolution in healthy and premalignant tissues: implications for early cancer interception strategies","volume":"16","author":"Rane","year":"2023","journal-title":"Cancer Prev Res (Phila)"},{"issue":"3","key":"10.1016\/j.annonc.2025.10.1239_bib51","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","article-title":"Fibroblast heterogeneity and immunosuppressive environment in human breast cancer","volume":"33","author":"Costa","year":"2018","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1239_bib52","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1038\/s41467-020-18916-5","article-title":"Single-cell RNA sequencing highlights the role of inflammatory cancer-associated fibroblasts in bladder urothelial carcinoma","volume":"11","author":"Chen","year":"2020","journal-title":"Nat Commun"},{"issue":"7693","key":"10.1016\/j.annonc.2025.10.1239_bib53","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1239_bib54","doi-asserted-by":"crossref","first-page":"6619","DOI":"10.1038\/s41467-022-34395-2","article-title":"Pan-cancer single-cell analysis reveals the heterogeneity and plasticity of cancer-associated fibroblasts in the tumor microenvironment","volume":"13","author":"Luo","year":"2022","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.annonc.2025.10.1239_bib55","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.cell.2015.01.043","article-title":"TGF-\u03b2 promotes heterogeneity and drug resistance in squamous cell carcinoma","volume":"160","author":"Oshimori","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.annonc.2025.10.1239_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1286850","article-title":"Heterogeneity of tertiary lymphoid structures in cancer","volume":"14","author":"You","year":"2023","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.annonc.2025.10.1239_bib57","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","article-title":"The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition","volume":"22","author":"Hegde","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1239_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1239_bib59","doi-asserted-by":"crossref","DOI":"10.1080\/01443615.2024.2321323","article-title":"Construction of a ferroptosis and hypoxia-related gene signature in cervical cancer to assess tumour immune microenvironment and predict prognosis","volume":"44","author":"Wu","year":"2024","journal-title":"J Obstet Gynaecol"},{"issue":"12","key":"10.1016\/j.annonc.2025.10.1239_bib60","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.ccell.2021.10.009","article-title":"Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification","volume":"39","author":"Leader","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.annonc.2025.10.1239_bib61","article-title":"Role of hypoxia in the tumor microenvironment and targeted therapy","volume":"12","author":"Chen","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.annonc.2025.10.1239_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1175563","article-title":"Association between pH regulation of the tumor microenvironment and immunological state","volume":"13","author":"Hosonuma","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.annonc.2025.10.1239_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2021.100787","article-title":"Hypoxia as a driver of resistance to immunotherapy","volume":"59","author":"Kopecka","year":"2021","journal-title":"Drug Resist Updat"},{"issue":"8080","key":"10.1016\/j.annonc.2025.10.1239_bib64","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/s41586-025-09278-3","article-title":"Neutrophils drive vascular occlusion, tumour necrosis and metastasis","volume":"645","author":"Adrover","year":"2025","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.annonc.2025.10.1239_bib65","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.immuni.2020.03.001","article-title":"CXCR1 and CXCR2 chemokine receptor agonists produced by tumors induce neutrophil extracellular traps that interfere with immune cytotoxicity","volume":"52","author":"Teijeira","year":"2020","journal-title":"Immunity"},{"issue":"7","key":"10.1016\/j.annonc.2025.10.1239_bib66","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/s41556-019-0346-x","article-title":"Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments","volume":"21","author":"Janiszewska","year":"2019","journal-title":"Nat Cell Biol"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1239_bib67","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s40425-018-0479-7","article-title":"High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors","volume":"6","author":"Maleki Vareki","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2025.10.1239_bib68","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","article-title":"Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer","volume":"7","author":"Anagnostou","year":"2017","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.annonc.2025.10.1239_bib69","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.trecan.2022.01.013","article-title":"The spectrum of sex differences in cancer","volume":"8","author":"Rubin","year":"2022","journal-title":"Trends Cancer"},{"issue":"10","key":"10.1016\/j.annonc.2025.10.1239_bib70","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/nri.2016.90","article-title":"Sex differences in immune responses","volume":"16","author":"Klein","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"15","key":"10.1016\/j.annonc.2025.10.1239_bib71","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1158\/1078-0432.CCR-21-0136","article-title":"Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion","volume":"27","author":"Conforti","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.annonc.2025.10.1239_bib72","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S1470-2045(18)30261-4","article-title":"Cancer immunotherapy efficacy and patients\u2019 sex: a systematic review and meta-analysis","volume":"19","author":"Conforti","year":"2018","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2025.10.1239_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100251","article-title":"Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials","volume":"6","author":"Conforti","year":"2021","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.annonc.2025.10.1239_bib74","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/jnci\/djz094","article-title":"Sex-based heterogeneity in response to lung cancer immunotherapy: a systematic review and meta-analysis","volume":"111","author":"Conforti","year":"2019","journal-title":"J Natl Cancer Inst"},{"issue":"8072","key":"10.1016\/j.annonc.2025.10.1239_bib75","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41586-025-09111-x","article-title":"Targeting GRPR for sex hormone-dependent cancer after loss of E-cadherin","volume":"643","author":"Raymond","year":"2025","journal-title":"Nature"},{"issue":"7915","key":"10.1016\/j.annonc.2025.10.1239_bib76","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/s41586-022-04522-6","article-title":"Androgen receptor activity in T cells limits checkpoint blockade efficacy","volume":"606","author":"Guan","year":"2022","journal-title":"Nature"},{"issue":"7915","key":"10.1016\/j.annonc.2025.10.1239_bib77","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1038\/s41586-022-04833-8","article-title":"Androgen receptor blockade promotes response to BRAF\/MEK-targeted therapy","volume":"606","author":"Vellano","year":"2022","journal-title":"Nature"},{"issue":"6230","key":"10.1016\/j.annonc.2025.10.1239_bib78","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.annonc.2025.10.1239_bib79","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41588-023-01499-4","article-title":"Mismatch repair deficiency is not sufficient to elicit tumor immunogenicity","volume":"55","author":"Westcott","year":"2023","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1239_bib80","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12943-021-01331-9","article-title":"Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer","volume":"20","author":"Fang","year":"2021","journal-title":"Mol Cancer"},{"issue":"14","key":"10.1016\/j.annonc.2025.10.1239_bib81","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1158\/1078-0432.CCR-21-1355","article-title":"Intratumor heterogeneity and antitumor immunity shape one another bidirectionally","volume":"28","author":"Wolf","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1239_bib82","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1001\/jamaoncol.2015.3638","article-title":"Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer","volume":"2","author":"McLaughlin","year":"2016","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2025.10.1239_bib83","doi-asserted-by":"crossref","first-page":"249","DOI":"10.5858\/arpa.2015-0303-SA","article-title":"Non-small cell lung cancer, PD-L1, and the pathologist","volume":"140","author":"Kerr","year":"2016","journal-title":"Arch Pathol Lab Med"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1239_bib84","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/annonc\/mdv489","article-title":"Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies","volume":"27","author":"Ilie","year":"2016","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2025.10.1239_bib85","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41591-024-03083-7","article-title":"Botensilimab plus balstilimab in relapsed\/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial","volume":"30","author":"Bullock","year":"2024","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1239_bib86","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"issue":"52","key":"10.1016\/j.annonc.2025.10.1239_bib87","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aba0759","article-title":"Regulatory T cell control of systemic immunity and immunotherapy response in liver metastasis","volume":"5","author":"Lee","year":"2020","journal-title":"Sci Immunol"},{"issue":"5","key":"10.1016\/j.annonc.2025.10.1239_bib88","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1158\/2326-6066.CIR-16-0325","article-title":"Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC","volume":"5","author":"Tumeh","year":"2017","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1239_bib89","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-70788-3","article-title":"Bone metastasis is associated with acquisition of mesenchymal phenotype and immune suppression in a model of spontaneous breast cancer metastasis","volume":"10","author":"Monteran","year":"2020","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.annonc.2025.10.1239_bib90","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1016\/j.ccell.2021.09.005","article-title":"Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment","volume":"39","author":"Kfoury","year":"2021","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.annonc.2025.10.1239_bib91","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1158\/2159-8290.CD-18-1489","article-title":"Molecular profiling reveals unique immune and metabolic features of melanoma brain metastases","volume":"9","author":"Fischer","year":"2019","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1239_bib92","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s13059-021-02363-6","article-title":"Multi-omic profiling of lung and liver tumor microenvironments of metastatic pancreatic cancer reveals site-specific immune regulatory pathways","volume":"22","author":"Ho","year":"2021","journal-title":"Genome Biol"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1239_bib93","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jso.23943","article-title":"The indolent nature of pulmonary metastases from ductal adenocarcinoma of the pancreas","volume":"112","author":"Downs-Canner","year":"2015","journal-title":"J Surg Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2025.10.1239_bib94","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/nrc1098","article-title":"The pathogenesis of cancer metastasis: the \u2018seed and soil\u2019 hypothesis revisited","volume":"3","author":"Fidler","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.annonc.2025.10.1239_bib95","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1158\/2159-8290.CD-22-1427","article-title":"Late-stage metastatic melanoma emerges through a diversity of evolutionary pathways","volume":"13","author":"Spain","year":"2023","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.annonc.2025.10.1239_bib96","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nm.4040","article-title":"Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition","volume":"22","author":"Hata","year":"2016","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.annonc.2025.10.1239_bib97","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jtho.2018.03.008","article-title":"Clinical features and management of acquired resistance to PD-1 axis inhibitors in 26 patients with advanced non-small cell lung cancer","volume":"13","author":"Gettinger","year":"2018","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1239_bib98","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cncr.32522","article-title":"Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy","volume":"126","author":"Pires da Silva","year":"2020","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.annonc.2025.10.1239_bib99","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.ccell.2018.11.003","article-title":"The link between the multiverse of immune microenvironments in metastases and the survival of colorectal cancer patients","volume":"34","author":"Van den Eynde","year":"2018","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.annonc.2025.10.1239_bib100","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.ccell.2018.11.012","article-title":"Immunodivergence in metastatic colorectal cancer","volume":"34","author":"de Andrea","year":"2018","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.annonc.2025.10.1239_bib101","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.trecan.2023.03.002","article-title":"Insights into the metastatic cascade through research autopsies","volume":"9","author":"Hessey","year":"2023","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1239_bib102","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.cell.2019.08.032","article-title":"UVB-induced tumor heterogeneity diminishes immune response in melanoma","volume":"179","author":"Wolf","year":"2019","journal-title":"Cell"},{"issue":"7966","key":"10.1016\/j.annonc.2025.10.1239_bib103","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s41586-023-06132-2","article-title":"In situ tumour arrays reveal early environmental control of cancer immunity","volume":"618","author":"Ortiz-Mu\u00f1oz","year":"2023","journal-title":"Nature"},{"issue":"42","key":"10.1016\/j.annonc.2025.10.1239_bib104","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2317694121","article-title":"Transcriptional repression by HDAC3 mediates T cell exclusion from Kras mutant lung tumors","volume":"121","author":"McGuire","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.annonc.2025.10.1239_bib105","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to T cell-mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2025.10.1239_bib106","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/j.ccell.2025.06.012","article-title":"Subclonal immune evasion in non-small cell lung cancer","volume":"43","author":"Dijkstra","year":"2025","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.annonc.2025.10.1239_bib107","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.ccr.2010.10.002","article-title":"CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation","volume":"18","author":"Rakhra","year":"2010","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.annonc.2025.10.1239_bib108","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/s41590-022-01215-0","article-title":"Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression","volume":"23","author":"Yeo","year":"2022","journal-title":"Nat Immunol"},{"key":"10.1016\/j.annonc.2025.10.1239_bib109","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/s43018-019-0020-z","article-title":"Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer","volume":"1","author":"Stewart","year":"2020","journal-title":"Nat Cancer"},{"issue":"6","key":"10.1016\/j.annonc.2025.10.1239_bib110","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a029611","article-title":"Chromosomal instability as a driver of tumor heterogeneity and evolution","volume":"7","author":"Bakhoum","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"13","key":"10.1016\/j.annonc.2025.10.1239_bib111","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.3390\/cancers14133275","article-title":"Circulating tumor DNA-based genomic profiling assays in adult solid tumors for precision oncology: recent advancements and future challenges","volume":"14","author":"Chan","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.annonc.2025.10.1239_bib112","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/s41591-018-0134-3","article-title":"Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab","volume":"24","author":"Gandara","year":"2018","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.annonc.2025.10.1239_bib113","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004440","article-title":"Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer","volume":"10","author":"Lopez de Rodas","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"23","key":"10.1016\/j.annonc.2025.10.1239_bib114","doi-asserted-by":"crossref","first-page":"4711","DOI":"10.1158\/1078-0432.CCR-22-3653","article-title":"Facts and hopes on neutralization of protumor inflammatory mediators in cancer immunotherapy","volume":"29","author":"Olivera","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1239_bib115","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1038\/s41467-020-15726-7","article-title":"Transcriptional downregulation of MHC class I and melanoma de-differentiation in resistance to PD-1 inhibition","volume":"11","author":"Lee","year":"2020","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.annonc.2025.10.1239_bib116","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.it.2009.01.006","article-title":"NK cell education: not an on-off switch but a tunable rheostat","volume":"30","author":"Brodin","year":"2009","journal-title":"Trends Immunol"},{"issue":"2","key":"10.1016\/j.annonc.2025.10.1239_bib117","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1158\/2159-8290.CD-23-0519","article-title":"NKG2A is a therapeutic vulnerability in immunotherapy resistant MHC-I heterogeneous triple-negative breast cancer","volume":"14","author":"Taylor","year":"2024","journal-title":"Cancer Discov"},{"issue":"7945","key":"10.1016\/j.annonc.2025.10.1239_bib118","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41586-022-05593-1","article-title":"\u03b3\u03b4 T cells are effectors of immunotherapy in cancers with HLA class I defects","volume":"613","author":"de Vries","year":"2023","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.annonc.2025.10.1239_bib119","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1158\/2159-8290.CD-20-0756","article-title":"A critical role for Fas-mediated off-target tumor killing in T-cell immunotherapy","volume":"11","author":"Upadhyay","year":"2021","journal-title":"Cancer Discov"},{"issue":"23","key":"10.1016\/j.annonc.2025.10.1239_bib120","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1609279","article-title":"T-cell transfer therapy targeting mutant KRAS in cancer","volume":"375","author":"Tran","year":"2016","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.annonc.2025.10.1239_bib121","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","article-title":"Neoantigen T-cell receptor gene therapy in pancreatic cancer","volume":"386","author":"Leidner","year":"2022","journal-title":"N Engl J Med"},{"issue":"7662","key":"10.1016\/j.annonc.2025.10.1239_bib122","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.annonc.2025.10.1239_bib123","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"issue":"10","key":"10.1016\/j.annonc.2025.10.1239_bib124","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"issue":"26","key":"10.1016\/j.annonc.2025.10.1239_bib125","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2014-12-580068","article-title":"CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"125","author":"Maude","year":"2015","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.annonc.2025.10.1239_bib126","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1172\/JCI126397","article-title":"B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma","volume":"129","author":"Cohen","year":"2019","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1239_bib127","doi-asserted-by":"crossref","first-page":"5387","DOI":"10.1038\/s41467-019-13196-0","article-title":"On-target restoration of a split T cell-engaging antibody for precision immunotherapy","volume":"10","author":"Banaszek","year":"2019","journal-title":"Nat Commun"},{"issue":"16","key":"10.1016\/j.annonc.2025.10.1239_bib128","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1016\/j.cell.2023.06.020","article-title":"Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy","volume":"186","author":"Dolton","year":"2023","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.annonc.2025.10.1239_bib129","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1158\/2326-6066.CIR-22-0444","article-title":"Feasibility and safety of personalized, multi-target, adoptive cell therapy (IMA101): first-in-human clinical trial in patients with advanced metastatic cancer","volume":"11","author":"Tsimberidou","year":"2023","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"10.1016\/j.annonc.2025.10.1239_bib130","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/s41423-020-0515-7","article-title":"Allogeneic V\u03b39V\u03b42 T-cell immunotherapy exhibits promising clinical safety and prolongs the survival of patients with late-stage lung or liver cancer","volume":"18","author":"Xu","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"2","key":"10.1016\/j.annonc.2025.10.1239_bib131","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/s41590-019-0578-8","article-title":"Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1","volume":"21","author":"Crowther","year":"2020","journal-title":"Nat Immunol"},{"issue":"3","key":"10.1016\/j.annonc.2025.10.1239_bib132","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"20","key":"10.1016\/j.annonc.2025.10.1239_bib133","first-page":"2470","article-title":"Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed\/refractory large B-cell lymphoma","volume":"141","author":"Roddie","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.annonc.2025.10.1239_bib134","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1158\/2159-8290.CD-22-0964","article-title":"CD19\/CD20 bispecific chimeric antigen receptor (CAR) in naive\/memory T cells for the treatment of relapsed or refractory non-Hodgkin lymphoma","volume":"13","author":"Larson","year":"2023","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.annonc.2025.10.1239_bib135","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy-current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1239_bib136","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/imr.13281","article-title":"Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming","volume":"321","author":"Luri-Rey","year":"2024","journal-title":"Immunol Rev"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1239_bib137","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000325","article-title":"Cellular cytotoxicity is a form of immunogenic cell death","volume":"8","author":"Minute","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.annonc.2025.10.1239_bib138","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.coph.2013.04.006","article-title":"Tumour heterogeneity and immune-modulation","volume":"13","author":"Jamal-Hanjani","year":"2013","journal-title":"Curr Opin Pharmacol"},{"issue":"29","key":"10.1016\/j.annonc.2025.10.1239_bib139","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aat1435","article-title":"The immune system profoundly restricts intratumor genetic heterogeneity","volume":"3","author":"Milo","year":"2018","journal-title":"Sci Immunol"},{"issue":"6280","key":"10.1016\/j.annonc.2025.10.1239_bib140","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"issue":"6257","key":"10.1016\/j.annonc.2025.10.1239_bib141","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.annonc.2025.10.1239_bib142","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1038\/s41591-022-02163-w","article-title":"Persistent mutation burden drives sustained anti-tumor immune responses","volume":"29","author":"Niknafs","year":"2023","journal-title":"Nat Med"},{"issue":"5795","key":"10.1016\/j.annonc.2025.10.1239_bib143","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.annonc.2025.10.1239_bib144","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1158\/2159-8290.CD-18-0099","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","journal-title":"Cancer Discov"},{"issue":"17","key":"10.1016\/j.annonc.2025.10.1239_bib145","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"issue":"7559","key":"10.1016\/j.annonc.2025.10.1239_bib146","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.annonc.2025.10.1239_bib147","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1158\/1078-0432.CCR-21-3501","article-title":"The challenges of HLA class I loss in cancer immunotherapy: facts and hopes","volume":"28","author":"Aptsiauri","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1239_bib148","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.1038\/s41467-021-25962-0","article-title":"Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer","volume":"12","author":"Hammerl","year":"2021","journal-title":"Nat Commun"},{"issue":"5","key":"10.1016\/j.annonc.2025.10.1239_bib149","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41591-020-0860-1","article-title":"High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade","volume":"26","author":"Yuen","year":"2020","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.annonc.2025.10.1239_bib150","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41591-020-0856-x","article-title":"Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors","volume":"26","author":"Schalper","year":"2020","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.annonc.2025.10.1239_bib151","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/1750743X.2024.2379230","article-title":"Peripheral blood cytokines and outcomes with immune checkpoint blockade: a systematic review and meta-analysis","volume":"16","author":"Karol","year":"2024","journal-title":"Immunotherapy"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1239_bib152","article-title":"CD8(+) T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy","volume":"4","author":"Huseni","year":"2023","journal-title":"Cell Rep Med"},{"issue":"7749","key":"10.1016\/j.annonc.2025.10.1239_bib153","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41586-019-1032-7","article-title":"Neoantigen-directed immune escape in lung cancer evolution","volume":"567","author":"Rosenthal","year":"2019","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.annonc.2025.10.1239_bib154","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nri3175","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1239_bib155","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1038\/s41467-020-20059-6","article-title":"Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma","volume":"11","author":"Zhou","year":"2020","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.annonc.2025.10.1239_bib156","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.it.2023.10.007","article-title":"Tumor macrophage functional heterogeneity can inform the development of novel cancer therapies","volume":"44","author":"Nasir","year":"2023","journal-title":"Trends Immunol"},{"issue":"3","key":"10.1016\/j.annonc.2025.10.1239_bib157","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/imm.13067","article-title":"Intratumoral regulatory T cells: markers, subsets and their impact on anti-tumor immunity","volume":"157","author":"Yano","year":"2019","journal-title":"Immunology"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1239_bib158","doi-asserted-by":"crossref","first-page":"6804","DOI":"10.1038\/s41467-021-26870-z","article-title":"Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions","volume":"12","author":"Schmelz","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.annonc.2025.10.1239_bib159","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1136\/gutjnl-2012-302529","article-title":"Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer","volume":"62","author":"Jacobetz","year":"2013","journal-title":"Gut"},{"issue":"7934","key":"10.1016\/j.annonc.2025.10.1239_bib160","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41586-022-05272-1","article-title":"LRRC15(+) myofibroblasts dictate the stromal setpoint to suppress tumour immunity","volume":"611","author":"Krishnamurty","year":"2022","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.annonc.2025.10.1239_bib161","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1158\/2159-8290.CD-19-1384","article-title":"Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer","volume":"10","author":"Kieffer","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.annonc.2025.10.1239_bib162","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.semcancer.2017.03.001","article-title":"Cancer acidity: an ultimate frontier of tumor immune escape and a novel target of immunomodulation","volume":"43","author":"Huber","year":"2017","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"10.1016\/j.annonc.2025.10.1239_bib163","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002088","article-title":"Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck","volume":"9","author":"Zandberg","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.annonc.2025.10.1239_bib164","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41591-024-02803-3","article-title":"Longitudinal gut microbiome changes in immune checkpoint blockade-treated advanced melanoma","volume":"30","author":"Bjork","year":"2024","journal-title":"Nat Med"},{"issue":"6391","key":"10.1016\/j.annonc.2025.10.1239_bib165","doi-asserted-by":"crossref","DOI":"10.1126\/science.aan5931","article-title":"Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells","volume":"360","author":"Ma","year":"2018","journal-title":"Science"},{"issue":"6371","key":"10.1016\/j.annonc.2025.10.1239_bib166","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1126\/science.aan4236","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","journal-title":"Science"},{"issue":"6371","key":"10.1016\/j.annonc.2025.10.1239_bib167","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1126\/science.aan3706","article-title":"Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors","volume":"359","author":"Routy","year":"2018","journal-title":"Science"},{"issue":"6529","key":"10.1016\/j.annonc.2025.10.1239_bib168","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1126\/science.abb5920","article-title":"Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients","volume":"371","author":"Baruch","year":"2021","journal-title":"Science"},{"issue":"15","key":"10.1016\/j.annonc.2025.10.1239_bib169","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1016\/j.cell.2023.06.002","article-title":"Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity","volume":"186","author":"Ma","year":"2023","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.annonc.2025.10.1239_bib170","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1084\/jem.20031435","article-title":"Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients","volume":"200","author":"Thomas","year":"2004","journal-title":"J Exp Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425062179?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425062179?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T21:00:07Z","timestamp":1777582807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753425062179"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":170,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0923753425062179"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.10.1239","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intratumoral heterogeneity and immunotherapy resistance: clinical implications","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.10.1239","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}